# DESCRIPTION

## BACKGROUND

- motivate immune complex considerations

## SUMMARY

- introduce complement mediated disorders
- describe formation of multivalent immune complexes
- motivate strategies to prevent or minimize complex formation
- describe washout period to reduce first antibody levels
- describe apheresis procedure to remove first antibody
- describe use of peptide antigens to bind to first antibody
- describe methods for treating complement mediated disorders
- describe methods for determining adjusted regimen of second antibody
- describe additional techniques to clear or enhance clearance of first antibody
- define anti-C5 antibody
- specify threshold level
- determine threshold level
- administer anti-C5 antibody
- specify dosing regimen
- administer to patient
- describe anti-C5 antibody embodiments
- describe administration regimens
- describe patient populations
- describe biological samples
- describe treatment methods
- describe complement mediated disorders
- describe efficacy assessment
- describe use of second anti-C5 antibody
- describe specific second anti-C5 antibodies

## DETAILED DESCRIPTION

### I. General Definitions

- define "and/or"
- define "about"
- define "range of values"
- define "plurality"
- define "first" and "second"
- define "substantially"
- define "marker"
- define "panel"
- define "modulate"
- define "detecting"
- define "determining"
- define "treat"

### II. Anti-C5 Antibodies

- define antibody
- describe anti-C5 antibodies
- exemplify ravulizumab
- exemplify other anti-C5 antibodies
- define CDR boundaries
- describe variant Fc constant region
- summarize prior art
- describe variant Fc constant regions
- specify antibody properties
- outline methods for determining antibody binding
- describe methods for determining inhibition of C5 cleavage
- outline immunological techniques for measuring C5 and its split products
- detail hemolytic assays for determining inhibitory activity of anti-C5 antibodies
- explain CH50 eq assay for quantifying C5 activity and inhibition
- discuss generation and administration of anti-C5 antibodies

### III. Multivalent Immune Complexes

- define multivalent immune complexes
- describe methods to prevent or minimize formation

### IV. Complement Mediated Disorders

- describe methods for treating complement mediated disorders

### V. Therapeutic Regimens and Adjusted Regimens

- describe therapeutic regimens
- describe adjusted regimens
- specify embodiments of anti-C5 antibodies
- define therapeutic regimens
- specify anti-C5 antibody compositions
- describe administration doses for pediatric patients
- describe administration doses for adult patients
- specify adjusted regimens for pediatric patients
- specify adjusted regimens for adult patients
- describe administration schedules

### VI. Methods of Treatment

- outline treatment method

### VII. Methods of Determining Adjusted Regimens

- outline regimen determination method

### VIII. Methods for Switching a Patient from a First C5-Antibody to a Second C5-Antibody

- outline switching method

### IX. Additional Treatments

- describe additional techniques

## EXAMPLE

### Example 1

- motivate formation of multivalent immune complexes
- describe methods for assessing complex formation
- present results of complex formation experiments
- discuss implications of multivalent complex formation

